MDD Study 1: Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of an investigational medication given as monotherapy in MDD
MDD Study 2: Phase 2, Multicenter, Randomized, Double-Blind Evaluation of the Efficacy & Safety of an oral investigational medication or Placebo for the Reduction of Symptoms of MDD in Adults
MDD Study 2: Phase 2, Multicenter, Randomized, Double-Blind Evaluation of the Efficacy & Safety of an oral investigational medication or Placebo for the Reduction of Symptoms of MDD in Adults
Mechanism: potent, selective activator of Kv7.2/7.3 potassium channels
Age: 18 - 75
BMI: ≥ 18, ≤ 35
Depressive Episode Duration: 2-24 months
Cannabis: If + at screening, screening phase may be extended by 4 weeks to allow for negative testing. Must test negative prior to the baseline (2nd) visit.
Therapy: Ongoing allowed if stable for at l
Mechanism: potent, selective activator of Kv7.2/7.3 potassium channels
Age: 18 - 75
BMI: ≥ 18, ≤ 35
Depressive Episode Duration: 2-24 months
Cannabis: If + at screening, screening phase may be extended by 4 weeks to allow for negative testing. Must test negative prior to the baseline (2nd) visit.
Therapy: Ongoing allowed if stable for at least 12 weeks prior to screening
Exclusionary Diagnoses:
No lifetime history: Bipolar disorders, schizophrenia or other psychotic disorders, borderline or narcissistic personality disorders, dementia, delirium, amnesia, neurodegenerative disease or seizure disorder
Within the last 12 months: No OCD, eating or feeding disorders
Within the last 6 months: No AUD or SUD, excluding nicotine
Within the last month: No PTSD
Additional Exclusion Criteria: No East Asian or Southeast Asian participants (a parent or grandparent from an East Asian or Southeast Asian country)
Study Duration: 12 weeks
Payment: $125 each clinic visit, $62.50 for remote call, up to $987.50 if all visits are completed
MDD Study 2: Phase 2, Multicenter, Randomized, Double-Blind Evaluation of the Efficacy & Safety of an oral investigational medication or Placebo for the Reduction of Symptoms of MDD in Adults
MDD Study 2: Phase 2, Multicenter, Randomized, Double-Blind Evaluation of the Efficacy & Safety of an oral investigational medication or Placebo for the Reduction of Symptoms of MDD in Adults
MDD Study 2: Phase 2, Multicenter, Randomized, Double-Blind Evaluation of the Efficacy & Safety of an oral investigational medication or Placebo for the Reduction of Symptoms of MDD in Adults
Cannabis: Must be willing to discontinue at least 14 days prior to the baseline (2nd) visit
Therapy: Ongoing allowed if stable for at least 8 weeks prior to screening
Exclusionary Diagnoses: Treatment-resistant MDD, MDD with psychotic features, other psychotic disorder history, current bipolar disorder or related diagnosis, OCD, ADHD, antisocial or borderline personality disorders
Additional Exclusion Criteria: All nicotine products must be discontinued at least 2 weeks before baseline (2nd visit). No night shifts during trial.
Study Duration: 14 weeks
Payment: $200 each clinic visit, up to $1600 if all visits are completed
MDD Study 3 (on temporary hold): Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Oral investigational medication versus Placebo in Participants with MDD
MDD Study 2: Phase 2, Multicenter, Randomized, Double-Blind Evaluation of the Efficacy & Safety of an oral investigational medication or Placebo for the Reduction of Symptoms of MDD in Adults
MDD Study 3 (on temporary hold): Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Oral investigational medication versus Placebo in Participants with MDD
Mechanism: kappa opioid receptor antagonist designed to modulate dopamine and reward processing pathways
Age: 18 - 65
BMI: ≤ 35
Depressive Episode Duration: 4 weeks – 12 months
Cannabis: Must be negative by baseline (2nd) visit
Therapy: Ongoing allowed if stable for at least 4 weeks prior to screening
Exclusionary Diagnoses:
No lifetime
Mechanism: kappa opioid receptor antagonist designed to modulate dopamine and reward processing pathways
Age: 18 - 65
BMI: ≤ 35
Depressive Episode Duration: 4 weeks – 12 months
Cannabis: Must be negative by baseline (2nd) visit
Therapy: Ongoing allowed if stable for at least 4 weeks prior to screening
Exclusionary Diagnoses:
No lifetime history bipolar disorders, schizophrenia, schizoaffective disorder, schizophreniform, OCD, PTSD or seizures (unless childhood febrile seizures)
Within the last 3 years: No anorexia, bulimia or BED
Within the last year or currently: No personality disorders
Additional Exclusion Criteria: Useful vision in only 1 eye, corneal transplant in either eye, severe dry eye syndrome, or family history of corneal dystrophy
Study Duration: 12 weeks
Payment: $200 screen ($100 clinic visit, $100 eye exam). Clinic: $75-$100. Up to $1000 if all visits are completed
MDD Study 3: A Multi-center, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of an investigational medication in the Treatment of Adults with MDD
Postpartum Depression Study: Multicenter, Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of an investigational medication for Injection in the Treatment of Patients with Postpartum Depression
MDD Study 3 (on temporary hold): Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Oral investigational medication versus Placebo in Participants with MDD
Mechanism: small molecule which targets Sirtuin 6 (SIRT6). An NAD-dependent enzyme, SIRT6 modulates gene expression, metabolism, and repair associated with MDD, the activation of which is thought to alleviate depression
Age: 18 - 65
Sex: Female at birth only
BMI: ≥ 18, ≤ 45
Depressive Episode Duration: 6 weeks – 2 years
Cannabis: Not exclu
Mechanism: small molecule which targets Sirtuin 6 (SIRT6). An NAD-dependent enzyme, SIRT6 modulates gene expression, metabolism, and repair associated with MDD, the activation of which is thought to alleviate depression
Age: 18 - 65
Sex: Female at birth only
BMI: ≥ 18, ≤ 45
Depressive Episode Duration: 6 weeks – 2 years
Cannabis: Not exclusionary if they do not meet criteria for moderate or severe SUD
Therapy: No CBT, others allowed if stable for at least 3 months prior to screening
Exclusionary Diagnoses:
No lifetime history of MDD with psychotic features, schizophrenia or other psychotic disorders, bipolar disorders, personality disorders, or anaphylaxis to any prior medications. No history of seizures (up to 2 episodes of childhood febrile seizure okay).
No current diagnosis of peripartum depression, panic disorder, OCD, ADHD, PTSD, anorexia, or bulimia
Additional Exclusion Criteria: on antidepressant therapy and in remission just prior to onset of current MDE, major trauma or surgery within 3 months of screening
Study Duration: 11 weeks
Payment: Clinic visits: $125, up to $1,000 if all visits are completed
Postpartum Depression Study: Multicenter, Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of an investigational medication for Injection in the Treatment of Patients with Postpartum Depression
Postpartum Depression Study: Multicenter, Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of an investigational medication for Injection in the Treatment of Patients with Postpartum Depression
Postpartum Depression Study: Multicenter, Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of an investigational medication for Injection in the Treatment of Patients with Postpartum Depression
Mechanism: a unique, prodrug that is converted in vivo to an active drug metabolite, 4-hydroxy-diisopropyltryptamine, or 4-OH-DiPT. Although it possesses pharmacology and intense psychedelic effects similar to those of the active metabolite of psilocybin, the psychoactive state lasts for only about half as long.
Age: 18 - 65
BMI: N/A
Depr
Mechanism: a unique, prodrug that is converted in vivo to an active drug metabolite, 4-hydroxy-diisopropyltryptamine, or 4-OH-DiPT. Although it possesses pharmacology and intense psychedelic effects similar to those of the active metabolite of psilocybin, the psychoactive state lasts for only about half as long.
Age: 18 - 65
BMI: N/A
Depressive Episode: Patient is < 15 months postpartum with MDE starting between 2nd trimester through 4 weeks following delivery
Cannabis: If + UDS at screening, must be willing to discontinue and test negative at dosing day
Therapy: Okay if stable for at least 30 days prior to screening
Exclusionary Diagnoses:
No lifetime history of postpartum psychosis, bipolar disorders, schizophrenia, schizoaffective disorder, psychosis, or borderline personality disorder
No 1st degree family history of psychosis or bipolar disorders
No current treatment-resistant depressive episode
No history of seizures aside from childhood febrile seizures
Additional Exclusion Criteria: Must have stopped breastfeeding before screening appointment
Study Duration: 7 weeks
Payment: Clinic visits: $200, up to $1,200 if all visits are completed
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.